Gestational Trophoblastic Disease Market Research Report – Forecast to 2023

**Description:**

Global Gestational Trophoblastic Disease Research Report: By Type (Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, and Others), by Treatment (Surgery, Suction Dilation and Curettage, and Others), by End User—Forecast Till 2023

**Market Scenario**

The global gestational trophoblastic disease market is expected to grow significantly at a healthy CAGR during the forecast period from 2018 to 2023. Gestational trophoblastic disease (GTD) comprises a group of interrelated ailments that arise from the placental trophoblastic tissue. This can occur after normal or abnormal fertilization and is characterized by a distinct tumor marker, β-subunit of human chorionic gonadotrophin (β HCG).

Increase in risk factors affecting this spectrum of disease is expected to drive the growth of the market. These risk factors include high maternal age, the rise in ectopic pregnancies and excessive smoking. According to the American Lung Association, cigarette smoking kills an estimated 201,770 women annually in the US. Also, the increase in innovations in the field of oncology in anticipated to contribute significantly to the growth in this market. For instance, as on 11th October 2018, Bristol-Myers Squibb Company and Compugen Ltd. announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. Compugen Ltd., being a therapeutic discovery company, consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Moreover, high risk of recurrence of the tumors, even after single or multi-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hamper the market growth. Also, mismanagement of the disease with unclear or no guidelines in different regions may curb the growth of gestational trophoblastic disease during the assessment period. Some of the forms of the gestational trophoblastic disease start to show symptoms only after it reaches stage III. At this stage, it might have already spread to other parts of the body. According to the American Society of Clinical Oncology (ASCO), about 35% of women with placental-site trophoblastic tumor have had the cancer spread before it was diagnosed.

**Segmentation**

The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.

The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.

The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease, whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.

The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation
and curettage (D&C), and radiation therapy.

the market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.

The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.

The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players


Regional Market Summary

Global Gestational Trophoblastic Disease Market Share (%), by Region, 2017

Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)

Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.

Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.

Global Gestational Trophoblastic Disease Market, by Type

- Hydatidiform mole
- Complete
- Partial
- Invasive
- Choriocarcinoma
- Placental-site trophoblastic tumor
- Epithelioid trophoblastic tumor
- Others

Global Gestational Trophoblastic Disease Market, by Treatment

- Surgery
- Abdominal hysterectomy
- Vaginal hysterectomy
- Chemotherapy
- Suction dilation and curettage (D&C)
Radiation Therapy
- External beam radiation therapy

Global Gestational Trophoblastic Disease Market, by End user
- Hospital and clinics
- Diagnostic centers
- Others

Global Gestational Trophoblastic Disease Market, by Region
- Americas
  - North America
  - US
  - Canada
  - South America
- Europe
  - Western Europe
  - Germany
  - France
  - Italy
  - Spain
  - UK
  - Rest of Western Europe
  - Eastern Europe
- Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
- Middle East & Africa
  - Middle East
  - Africa

Contents:

Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Gestational Trophoblastic Disease Market, by Type
6.1 Introduction
6.2 Hydatidiform mole
6.2.1 Complete
Market Estimates & Forecast, by Region, 2018–2023
6.2.2 Partial
Market Estimates & Forecast, by Region, 2018–2023
6.3 Choriocarcinoma
Market Estimates & Forecast, by Region, 2018–2023
6.4 Placental-site trophoblastic tumor
Market Estimates & Forecast, by Region, 2018–2023
6.5 Epithelioid trophoblastic tumor
Market Estimates & Forecast, by Region, 2018–2023
6.6 Others
Market Estimates & Forecast, by Region, 2018–2023

Chapter 7. Global Gestational Trophoblastic Disease Market, by Treatment
7.1 Introduction
7.2 Surgery
7.2.1 Abdominal hysterectomy
Market Estimates & Forecast, by Region, 2018–2023
7.2.2 Vaginal hysterectomy
Market Estimates & Forecast, by Region, 2018–2023
7.3 Chemotherapy
Market Estimates & Forecast, by Region, 2018–2023
7.4 Suction dilation and curettage (D&C)
Market Estimates & Forecast, by Region, 2018–2023
7.5 Radiation Therapy
7.5.1 External beam radiation therapy
Market Estimates & Forecast, by Region, 2018–2023

Chapter 8. Global Gestational Trophoblastic Disease Market, by End-user
8.1 Hospitals and Clinics
Market Estimates & Forecast, by Region, 2018–2023
8.2 Diagnostic Centers
Market Estimates & Forecast, by Region, 2018–2023
8.3 Others
Market Estimates & Forecast, by Region, 2018–2023

Chapter 9. Global Gestational Trophoblastic Disease Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa

Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Teva Pharmaceutical Industries Ltd.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis

11.2 Hikma Pharmaceuticals PLC
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis

11.3 Pfizer Inc.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis

11.5 Antares Pharma
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.5.5 SWOT Analysis

11.6 Mylan N.V.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis

11.7 Novartis AG
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis

11.8 BP Pharmaceuticals Laboratories Company
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Fresenius Kabi AG
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Accord Healthcare, Inc.
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Eli Lilly and Company
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Sanofi
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Bayer AG
11.13.1 Overview
11.13.2 Product Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.14 Amgen Inc.
11.14.1 Overview
11.14.2 Product Overview
11.14.3 Financials
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.15 Merck
11.15.1 Overview
11.15.2 Product Overview
11.15.3 Financials
11.15.4 Key Developments
11.15.5 SWOT Analysis

Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch

11.3 Predictions for the Gestational Trophoblastic Disease Industry

Chapter 12. Appendix

LIST OF TABLES

Table 1 Global Gestational Trophoblastic Disease Market Synopsis, 2018–2023
Table 2 Global Gestational Trophoblastic Disease Market Estimates and Forecast, 2018–2023 (USD Million)
Table 3 Global Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 4 Global Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 5 Global Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 6 Global Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 7 North America: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 8 North America: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 9 North America: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 10 North America: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 11 US: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 12 US: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 13 US: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 14 US: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 15 Canada: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 16 Canada: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 17 Canada: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 18 Canada: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 19 South America: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 20 South America: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 21 South America: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 22 South America: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 23 Europe: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 24 Europe: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 25 Europe: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 26 Europe: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 27 Western Europe: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 28 Western Europe: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 29 Western Europe: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 30 Western Europe: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 31 Eastern Europe: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 32 Eastern Europe: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 33 Eastern Europe: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 34 Eastern Europe: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 35 Asia-Pacific: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 36 Asia-Pacific: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 37 Asia-Pacific: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 38 Asia-Pacific: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
Table 39 Middle East & Africa: Gestational Trophoblastic Disease Market, by Type, 2018–2023 (USD Million)
Table 40 Middle East & Africa: Gestational Trophoblastic Disease Market, by Treatment, 2018–2023 (USD Million)
Table 41 Middle East & Africa: Gestational Trophoblastic Disease Market, by End-User, 2018–2023 (USD Million)
Table 42 Middle East & Africa: Gestational Trophoblastic Disease Market, by Region, 2018–2023 (USD Million)
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Gestational Trophoblastic Disease Market
Figure 3 Segmentation Market Dynamics for Global Gestational Trophoblastic Disease Market
Figure 4 Global Gestational Trophoblastic Disease Market Share, by Type, 2017 (%)
Figure 5 Global Gestational Trophoblastic Disease Market Share, by Treatment, 2017 (%)
Figure 6 Global Gestational Trophoblastic Disease Market Share, by End-User, 2017 (%)
Figure 7 Global Gestational Trophoblastic Disease Market Share, by Region, 2017 (%)
Figure 8 North America: Gestational Trophoblastic Disease Market Share, by Country, 2017 (%)
Figure 9 Europe: Gestational Trophoblastic Disease Market Share, by Country, 2017 (%)
Figure 10 Asia-Pacific: Gestational Trophoblastic Disease Market Share, by Country, 2017 (%)
Figure 11 Middle East & Africa: Gestational Trophoblastic Disease Market Share, by Country, 2017 (%)
Figure 12 Global Gestational Trophoblastic Disease Market: Company Share Analysis, 2017 (%)
Figure 13 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 14 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 15 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 16 Hikma Pharmaceuticals PLC: Key Financials
Figure 17 Hikma Pharmaceuticals PLC: Segmental Revenue
Figure 18 Hikma Pharmaceuticals PLC: Geographical Revenue
Figure 19 Pfizer Inc.: Key Financials
Figure 20 Pfizer Inc.: Segmental Revenue
Figure 21 Pfizer Inc.: Geographical Revenue
Figure 22 Bristol-Myers Squibb Company: Key Financials
Figure 23 Bristol-Myers Squibb Company: Segmental Revenue
Figure 24 Bristol-Myers Squibb Company: Geographical Revenue
Figure 25 Antares Pharma: Key Financials
Figure 26 Antares Pharma: Segmental Revenue
Figure 27 Antares Pharma: Geographical Revenue
Figure 28 Mylan N.V.: Key Financials
Figure 29 Mylan N.V.: Segmental Revenue
Figure 30 Mylan N.V.: Geographical Revenue
Figure 31 Novartis AG: Key Financials
Figure 32 Novartis AG: Segmental Revenue
Figure 33 Novartis AG: Geographical Revenue
Figure 34 BP Pharmaceuticals Laboratories Company: Key Financials
Figure 35 BP Pharmaceuticals Laboratories Company: Segmental Revenue
Figure 36 BP Pharmaceuticals Laboratories Company: Geographical Revenue
Figure 37 Fresenius Kabi AG: Key Financials
Figure 38 Fresenius Kabi AG: Segmental Revenue
Figure 39 Fresenius Kabi AG: Geographical Revenue
Figure 40 Accord Healthcare, Inc.: Key Financials
Figure 41 Accord Healthcare, Inc.: Segmental Revenue
Figure 42 Accord Healthcare, Inc.: Geographical Revenue
Figure 43 Eli Lilly and Company: Key Financials
Figure 44 Eli Lilly and Company: Segmental Revenue
Figure 45 Eli Lilly and Company: Geographical Revenue
Figure 46 Sanofi: Key Financials
Figure 47 Sanofi: Segmental Revenue
Figure 48 Sanofi: Geographical Revenue
Figure 49 Bayer AG: Key Financials
Figure 50 Bayer AG: Segmental Revenue
Figure 51 Bayer AG: Geographical Revenue
Figure 52 Amgen Inc.: Key Financials
Figure 53 Amgen Inc.: Segmental Revenue
Figure 54 Amgen Inc.: Geographical Revenue
Figure 55 Merck: Key Financials
Figure 56 Merck: Segmental Revenue
Figure 57 Merck: Geographical Revenue